Cognition Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Cognition Therapeutics, Inc. (CGTX) reported Increase Decrease In Operating Lease Liability of -$105.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-07
- Cognition Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$45.00K.
- Cognition Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$60.00K.
- Cognition Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$49.00K.
- Cognition Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$47.00K.
- Cognition Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$204.00K.
- Cognition Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$159.00K.
- Cognition Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$150.00K.
- Cognition Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2022 was -$121.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$105.00K 10-Q · filed 2026-08-07 | -$154.00K derived: sum of 3 quarters · filed 2026-08-07 | -$201.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$60.00K 10-Q · filed 2026-05-08 | -$109.00K derived: sum of 2 quarters · filed 2026-05-08 | -$156.00K derived: sum of 3 quarters · filed 2026-05-08 | -$203.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$96.00K derived: sum of 2 quarters · filed 2026-03-26 | -$143.00K derived: sum of 3 quarters · filed 2026-08-07 | -$204.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | -$47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$94.00K derived: sum of 2 quarters · filed 2026-08-07 | -$155.00K 10-Q · filed 2025-11-06 | -$200.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$47.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$108.00K 10-Q · filed 2026-08-07 | -$153.00K derived: sum of 3 quarters · filed 2026-08-07 | -$197.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$61.00K 10-Q · filed 2026-05-08 | -$106.00K derived: sum of 2 quarters · filed 2026-05-08 | -$150.00K derived: sum of 3 quarters · filed 2026-05-08 | -$194.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$45.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$89.00K derived: sum of 2 quarters · filed 2026-03-26 | -$133.00K derived: sum of 3 quarters · filed 2026-03-26 | -$159.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | -$44.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$88.00K derived: sum of 2 quarters · filed 2025-11-06 | -$114.00K 10-Q · filed 2025-11-06 | -$155.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$44.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$70.00K 10-Q · filed 2025-08-07 | -$111.00K derived: sum of 3 quarters · filed 2025-08-07 | -$150.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$26.00K 10-Q · filed 2025-05-07 | -$67.00K derived: sum of 2 quarters · filed 2025-05-07 | -$106.00K derived: sum of 3 quarters · filed 2025-05-07 | -$140.00K derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$80.00K derived: sum of 2 quarters · filed 2025-03-20 | -$114.00K derived: sum of 3 quarters · filed 2025-03-20 | -$150.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | -$39.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$73.00K derived: sum of 2 quarters · filed 2024-11-13 | -$109.00K 10-Q · filed 2024-11-13 | -$142.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$34.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$70.00K 10-Q · filed 2024-08-08 | -$103.00K derived: sum of 3 quarters · filed 2024-08-08 | -$140.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$36.00K 10-Q · filed 2024-05-07 | -$69.00K derived: sum of 2 quarters · filed 2024-05-07 | -$106.00K derived: sum of 3 quarters · filed 2024-05-07 | -$137.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$70.00K derived: sum of 2 quarters · filed 2024-03-26 | -$101.00K derived: sum of 3 quarters · filed 2024-03-26 | -$121.00K 10-K · filed 2024-03-26 |
| 2022-09-30 | -$37.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$68.00K derived: sum of 2 quarters · filed 2023-11-02 | -$88.00K 10-Q · filed 2023-11-02 | |
| 2022-06-30 | -$31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$51.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$20.00K 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |